{"log_id": 2155082226101702248, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 0.005021, "average": 0.984664, "min": 0.555082}, "location": {"width": 765, "top": 199, "height": 52, "left": 246}, "words": "普芦卡必利会在母乳中分泌。预计在治疗剂量下服用本品时,母乳喂养对新生儿/婴儿"}, {"probability": {"variance": 2e-06, "average": 0.998425, "min": 0.995152}, "location": {"width": 550, "top": 254, "height": 46, "left": 207}, "words": "没有影响。但由于缺乏人体数据,不建议在哺乳期间使用本品"}, {"probability": {"variance": 2.4e-05, "average": 0.996477, "min": 0.978495}, "location": {"width": 428, "top": 305, "height": 41, "left": 250}, "words": "动物研究显示本品对男性或女性生育力没有影响"}, {"probability": {"variance": 4e-06, "average": 0.998116, "min": 0.993848}, "location": {"width": 105, "top": 366, "height": 25, "left": 220}, "words": "【儿童用药】"}, {"probability": {"variance": 3e-06, "average": 0.998957, "min": 0.993198}, "location": {"width": 680, "top": 391, "height": 48, "left": 265}, "words": "目前该方面的临床数据较少,因此不建议儿童及小于18岁的青少年使用本品"}, {"probability": {"variance": 6e-06, "average": 0.997811, "min": 0.992965}, "location": {"width": 115, "top": 457, "height": 26, "left": 217}, "words": "【老年用药】"}, {"probability": {"variance": 0.00435, "average": 0.982889, "min": 0.631223}, "location": {"width": 560, "top": 488, "height": 44, "left": 254}, "words": "大于65岁的老年患者起始剂量为1mg,如有需要,可增加至2n"}, {"probability": {"variance": 8e-06, "average": 0.997339, "min": 0.990236}, "location": {"width": 155, "top": 547, "height": 30, "left": 220}, "words": "【药物相互作用】"}, {"probability": {"variance": 2.1e-05, "average": 0.996867, "min": 0.972583}, "location": {"width": 762, "top": 573, "height": 52, "left": 253}, "words": "体外数据表明,普芦卡必利发生药物相互作用的可能性低,治疗浓度的普芦卡必利预计"}, {"probability": {"variance": 0.00121, "average": 0.987312, "min": 0.80484}, "location": {"width": 801, "top": 620, "height": 52, "left": 216}, "words": "不会影响经CYP介导的合并用药的代谢。尽管普芦卡必利可能是P糖蛋白(P-gp)的弱的"}, {"probability": {"variance": 1.5e-05, "average": 0.997418, "min": 0.988069}, "location": {"width": 480, "top": 675, "height": 42, "left": 212}, "words": "底物,但其在临床相关浓度上并不是P糖蛋白抑制剂"}, {"probability": {"variance": 0.000165, "average": 0.99396, "min": 0.919275}, "location": {"width": 762, "top": 714, "height": 48, "left": 260}, "words": "酮康唑是一种有效的CYP3A4和P糖蛋白抑制剂,每日两次,每次200mg酮康唑可使"}, {"probability": {"variance": 0.005013, "average": 0.979939, "min": 0.54556}, "location": {"width": 805, "top": 758, "height": 51, "left": 217}, "words": "本品AUC增加大约40%。这种弱效应可能归因于抑制了P-糖蛋白介导的肾脏转运,并不具"}, {"probability": {"variance": 6.7e-05, "average": 0.995096, "min": 0.964722}, "location": {"width": 805, "top": 803, "height": 52, "left": 218}, "words": "有临床意义。在与其他P糖蛋白抑制剂,如维拉帕米、环孢素A、奎尼丁及酮康唑联合使"}, {"probability": {"variance": 1.3e-05, "average": 0.99752, "min": 0.982758}, "location": {"width": 802, "top": 850, "height": 49, "left": 220}, "words": "用时,也可以观察到类似程度的相互作用。本品也可能通过另一种肾脏转运蛋白分泌。抑制"}, {"probability": {"variance": 0.000101, "average": 0.99422, "min": 0.944933}, "location": {"width": 805, "top": 894, "height": 52, "left": 221}, "words": "与普芦卡必利主动分泌有关的所有转运蛋白(包括Pgp),理论上可能会使本品的暴露量"}, {"probability": {"variance": 4.9e-05, "average": 0.995135, "min": 0.981675}, "location": {"width": 87, "top": 965, "height": 24, "left": 224}, "words": "增加75%"}, {"probability": {"variance": 1.7e-05, "average": 0.997336, "min": 0.977668}, "location": {"width": 763, "top": 988, "height": 48, "left": 264}, "words": "针对健康受试者的研究显示,本品对华法林、地高辛、乙醇及帕罗西汀的药代动力学没"}, {"probability": {"variance": 7.7e-05, "average": 0.995972, "min": 0.957499}, "location": {"width": 803, "top": 1033, "height": 51, "left": 225}, "words": "有临床意义的影响。在与本品同时治疗期间,发现红霉素的血药浓度升高30%,其作用机"}, {"probability": {"variance": 0.000114, "average": 0.995361, "min": 0.948733}, "location": {"width": 803, "top": 1078, "height": 51, "left": 226}, "words": "制未完全明确,现有数据表明这是红霉素的药代动力学本身变异性高的结果,而不是本品的"}, {"probability": {"variance": 1e-06, "average": 0.998178, "min": 0.997044}, "location": {"width": 85, "top": 1146, "height": 27, "left": 227}, "words": "直接影响"}, {"probability": {"variance": 9e-06, "average": 0.998075, "min": 0.986429}, "location": {"width": 672, "top": 1172, "height": 48, "left": 267}, "words": "治疗剂量的丙磺舒、西咪替丁、红霉素及帕罗西汀不影响本品的药代动力学"}, {"probability": {"variance": 0.003801, "average": 0.982504, "min": 0.715017}, "location": {"width": 694, "top": 1218, "height": 48, "left": 270}, "words": "由于其作用机制,使用阿托品类药物可能会降低本品对5-HT4受体的介导作用"}, {"probability": {"variance": 3e-06, "average": 0.99802, "min": 0.995596}, "location": {"width": 113, "top": 1283, "height": 27, "left": 237}, "words": "【药物过量】"}, {"probability": {"variance": 0.010205, "average": 0.979927, "min": 0.351508}, "location": {"width": 762, "top": 1309, "height": 50, "left": 273}, "words": "在一项针对健康志愿者的研究中,当以每日一次20mg(推荐治疗剂量的10倍的本品"}, {"probability": {"variance": 1.8e-05, "average": 0.997029, "min": 0.979151}, "location": {"width": 683, "top": 1357, "height": 48, "left": 232}, "words": "进行治疗时,对本品仍具有良好的耐受性。药物过量可能会导致由药品已药"}, {"probability": {"variance": 0.002017, "average": 0.988651, "min": 0.745168}, "location": {"width": 770, "top": 1396, "height": 60, "left": 232}, "words": "致的症状,包括头痛、恶心和腹泻。本品药物过量时,无特异的治疗方"}, {"probability": {"variance": 0.002511, "average": 0.989223, "min": 0.71514}, "location": {"width": 622, "top": 1451, "height": 46, "left": 235}, "words": "量,必要时患者应该接受对症治疗,或使用支持性的医疗措施。如有需"}, {"probability": {"variance": 0, "average": 0.919963, "min": 0.919963}, "location": {"width": 156, "top": 1424, "height": 48, "left": 973}, "words": "腹"}, {"probability": {"variance": 0.001384, "average": 0.988948, "min": 0.827231}, "location": {"width": 407, "top": 1503, "height": 40, "left": 236}, "words": "呕吐引起的液体大量流失而导致的电解质紊乱"}, {"probability": {"variance": 6.5e-05, "average": 0.994333, "min": 0.977013}, "location": {"width": 114, "top": 1559, "height": 26, "left": 244}, "words": "【临床试验】"}, {"probability": {"variance": 0.001263, "average": 0.970547, "min": 0.909596}, "location": {"width": 112, "top": 1640, "height": 40, "left": 1088}, "words": "仅供存档"}], "language": 3}